Latest News and Updates

* (R) = Regulatory press releases

Feb 23, 2023

(R) Cantargia advances TRIFOUR trial to randomized stage following promising early safety and efficacy of nadunolimab in triple-negative breast cancer

Feb 14, 2023

Invitation to presentation of Cantargia’s Year-end report of 2022 on February 23 at 3.00 p.m. CET

Feb 1, 2023

(R) Cantargia announces appointment of Patrik Renblad as Chief Financial Officer

Jan 13, 2023

(R) Cantargia successfully concludes toxicity study with CAN10 antibody ahead of phase I clinical trial application

Nov 21, 2022

(R) Nomination Committee appointed ahead of 2023 Annual General Meeting

Nov 10, 2022

(R) Cantargia publishes interim report for third quarter 2022

Nov 8, 2022

(R) Cantargia’s CAN10 demonstrates positive activity in systemic sclerosis models in new data presented at ACR Convergence 2022

Nov 7, 2022

(R) Cantargia presents new data at SITC 2022 supporting nadunolimab’s promising antitumor clinical efficacy

Oct 28, 2022

Invitation to presentation of Cantargia’s report for the third quarter of 2022 on November 10 at 3.00 p.m. CET

Oct 14, 2022

(R) Cantargia reaches recruitment milestone and focuses nadunolimab development on upcoming randomized studies

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye

Press releases

(R) Cantargia advances TRIFOUR trial to randomized stage following promising early safety and efficacy of nadunolimab in triple-negative breast cancer

Invitation to presentation of Cantargia’s Year-end report of 2022 on February 23 at 3.00 p.m. CET

(R) Cantargia announces appointment of Patrik Renblad as Chief Financial Officer

(R) Cantargia successfully concludes toxicity study with CAN10 antibody ahead of phase I clinical trial application

(R) Nomination Committee appointed ahead of 2023 Annual General Meeting

(R) Cantargia publishes interim report for third quarter 2022

(R) Cantargia’s CAN10 demonstrates positive activity in systemic sclerosis models in new data presented at ACR Convergence 2022

(R) Cantargia presents new data at SITC 2022 supporting nadunolimab’s promising antitumor clinical efficacy

Invitation to presentation of Cantargia’s report for the third quarter of 2022 on November 10 at 3.00 p.m. CET

(R) Cantargia reaches recruitment milestone and focuses nadunolimab development on upcoming randomized studies

In media

Interview with CEO Hilde H. Steineger - 2025-10-24

Interview with CEO Hilde H. Steineger - 2025-10-07

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye interviews Interim CEO Damian Marron - 2025-02-07